Detalhe da pesquisa
1.
Optimized serum stability and specificity of an αvß6 integrin-binding peptide for tumor targeting.
J Biol Chem;
296: 100657, 2021.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33857478
2.
Discovery of a Transferrin Receptor 1-Binding Aptamer and Its Application in Cancer Cell Depletion for Adoptive T-Cell Therapy Manufacturing.
J Am Chem Soc;
144(30): 13851-13864, 2022 08 03.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35875870
3.
Biomaterials in Chimeric Antigen Receptor T-Cell Process Development.
Acc Chem Res;
53(9): 1724-1738, 2020 09 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32786336
4.
Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy.
Blood;
134(24): 2149-2158, 2019 12 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31697826
5.
Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy.
Ann Neurol;
86(1): 42-54, 2019 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31074527
6.
Manufacture of Chimeric Antigen Receptor T Cells from Mobilized Cyropreserved Peripheral Blood Stem Cell Units Depends on Monocyte Depletion.
Biol Blood Marrow Transplant;
25(2): 223-232, 2019 02.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30315942
7.
Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy.
N Engl J Med;
375(26): 2561-9, 2016 12 29.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28029927
8.
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults.
Blood;
129(25): 3322-3331, 2017 06 22.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28408462
9.
CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing.
BMC Cancer;
19(1): 895, 2019 Sep 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31500597
10.
Human CD19-Targeted Mouse T Cells Induce B Cell Aplasia and Toxicity in Human CD19 Transgenic Mice.
Mol Ther;
26(6): 1423-1434, 2018 06 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29735365
11.
Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy.
Blood;
127(20): 2406-10, 2016 05 19.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26907630
12.
Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL.
Blood;
127(24): 2980-90, 2016 06 16.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27118452
13.
Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells.
Immunol Rev;
257(1): 127-44, 2014 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24329794
14.
High Efficiency CRISPR/Cas9-mediated Gene Editing in Primary Human T-cells Using Mutant Adenoviral E4orf6/E1b55k "Helper" Proteins.
Mol Ther;
24(9): 1570-80, 2016 09 29.
Artigo
em Inglês
| MEDLINE
| ID: mdl-27203437
15.
Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases.
Mol Ther;
24(3): 570-81, 2016 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26502778
16.
Efficient Identification of Murine M2 Macrophage Peptide Targeting Ligands by Phage Display and Next-Generation Sequencing.
Bioconjug Chem;
26(8): 1811-7, 2015 Aug 19.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26161996
17.
T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia.
Blood;
122(18): 3138-48, 2013 Oct 31.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24030378
18.
Multiplexed gene transfer to a human T-cell line by combining Sleeping Beauty transposon system with methotrexate selection.
Biotechnol Bioeng;
112(7): 1429-36, 2015 Jul.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25808830
19.
Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells.
Blood;
119(1): 72-82, 2012 Jan 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22031866
20.
CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.
Blood;
119(17): 3940-50, 2012 Apr 26.
Artigo
em Inglês
| MEDLINE
| ID: mdl-22308288